NCT06095934Unknown不适用
Exploration of the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined With Neoantigen Peptide Vaccine and Chemotherapy in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
To evaluate the efficacy (ORR) and safety of anti PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC progressed after EGFR-TKI treatment and to provide new treatment methods for EGFR-TKI resistant patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient voluntarily joined this study and signed an informed consent form;
- •≥ 18 years old, both male and female;
- •Pathologically confirmed IIIB-IV stage NSCLC, with at least one measurable lesion that has not undergone local treatment (according to RECIST v1.1, the length of the measurable lesion on spiral CT or MRI scans is ≥ 10 mm or the short diameter of the enlarged lymph node is ≥ 15 mm);
- •Metastatic advanced EGFR mutated lung cancer confirmed by histology or cytology, with EGFR-TKI monotherapy or EGFR-TKI combined anti angiogenic therapy failing;
- •Patients who have received first-line chemotherapy in the past can be included in the inclusion criteria;
- •ECOG score: 0-2;
- •Expected survival time ≥ 12 weeks;
- •The functions of important organs meet the following requirements:Absolute neutrophil count ≥ 1.5 × 109/L;Absolute lymphocyte count ≥ 0.8 × 109/L;Platelets ≥ 80 × 109/L;Hemoglobin ≥ 90g/L;Bilirubin ≤ 1.5 × ULN (within 7 days before the first medication);ALT and AST ≤ 1.5 × ULN (within 7 days before the first medication); Serum creatinine ≤ 1.5 × ULN;
- •Thyroid stimulating hormone (TSH) ≤ 1 × ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously, and if FT3 and FT4 levels are normal, they can be included in the group level);
- •For female patients of childbearing age, effective methods of contraception should be used during the trial period and within 3 months after the last administration of treatment medication;
- •Agree to provide blood samples and histological specimens.
排除标准
- •The patient has any active autoimmune disease or a history of autoimmune disease;
- •The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage>10mg/day of prednisone or other therapeutic hormones) ;
- •The patient experienced severe allergic reactions to other monoclonal antibodies;
- •Suffering from hypertension and unable to achieve good control through antihypertensive medication treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg);
- •There are clinical symptoms or diseases of the heart that cannot be well controlled, such as:NYHA grade 2 or above heart failure;Unstable angina pectoris; Have experienced myocardial infarction within 1 year;Clinically significant supraventricular or ventricular arrhythmias require treatment or intervention; QTc>450ms (male); QTc>470ms (female);
- •Abnormal coagulation function (INR>2.0, PT>16s), with bleeding tendency or undergoing thrombolysis or anticoagulation treatment, allowing prophylactic use of low-dose aspirin and low molecular weight heparin;
- •Received previous anti-tumor immunotherapy and anti-tumor vaccine treatment;
- •The patient has active infection, unexplained fever ≥ 38.5 ° C within 7 days before medication, or baseline white blood cell count>15 × 109/L; Those who may have purulent or chronic infections, and the wound persists without healing;
- •Patients who have experienced bone metastasis have received palliative radiotherapy in areas greater than 5% of the bone marrow area within the 4 weeks prior to participating in this study;
- •The patient has previously received anti PD-1, anti PD-L1, and anti PD-L2 treatment;
- •Those who are known to be allergic to the components of recombinant humanized anti-PD-1 monoclonal antibody drugs and vaccines;
- •Pregnant or lactating women, or female patients with fertility who have not taken contraceptive measures;
- •Other malignant tumors (excluding basal cell or squamous cell carcinoma, superficial bladder cancer cancer, cervical carcinoma in situ or breast cancer) in the past 5 years;
- •Patients who participate in other clinical trials at the same time;
- •HIV positive; HCV positive; Uncontrolled active hepatitis B;
- •Those who have received live vaccination within 4 weeks before the start of treatment;
- •Patients with a history of asymptomatic brain metastasis who meet all the following conditions can be selected:During screening, brain imaging showed no evidence of immediate progression.There is currently no need to use glucocorticoids to treat brain metastases, and stable doses of anticonvulsants are allowed.
结局指标
主要结局
ORR
时间窗: three years
Exploration of the efficacy of anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC with previous EGFR-TKI treatment failure
次要结局
- PFS(three years)
- OS(three years)
研究者
Yang Yang
Principal Investigator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRelapsed/Refractory Peripheral T-cell LymphomaNCT05182957The First Affiliated Hospital of Soochow University31
招募中
2 期
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT06259721Jiangxi Provincial Cancer Hospital22
招募中
1 期
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory MalignanciesMalignancies MultipleNCT02961101Han weidong250
终止
1 期
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cARTHIV InfectionsNCT03787095National Institute of Allergy and Infectious Diseases (NIAID)5
招募中
2 期
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian CancerNeoadjuvant ChemotherapyAnti-PD-1Neoadjuvant ImmunotherapyOvarian CancerNCT04815408Second Affiliated Hospital, School of Medicine, Zhejiang University40